 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12345678910111213...4950» |
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Jan 24, 2024
P2, N=366, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Sep 2027 --> Jun 2026
- | albumin-bound paclitaxel / Generic mfg.
Trial completion, Trial completion date: ETNA: Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (clinicaltrials.gov) - Jan 22, 2024
P3, N=632, Completed, Sponsor: Fondazione Michelangelo
Trial primary completion date: Sep 2027 --> Jun 2026 Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Jan 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date: NeoATCT: A Phase ? Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2024
P2, N=32, Recruiting, Sponsor: Sichuan Provincial People's Hospital
Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Jan 2024 Trial completion date: Jul 2023 --> Sep 2025 | Trial primary completion date: Jul 2022 --> Mar 2025
- | 5-fluorouracil / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Journal: Ultrasensitive Upconversion Nanoparticle Immunoassay for Human Serum Cardiac Troponin I Detection Achieved with Resonant Waveguide Grating. (Pubmed Central) - Jan 18, 2024
The cTnI concentrations in human serum samples collected at different times during cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) chemotherapy in a breast cancer patient were measured by an immunosensor, and the results showed that the CEF chemotherapy did cause cardiotoxicity in the patient. Having a higher number of wells in such an array-based biosensor, the sensor can be developed as a high-throughput diagnostic tool for clinically important biomarkers.
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Cancer In Pregnancy And Maternal Chemotoxicity: A Retrospective Study From A Tertiary Center In Milan (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_1009;
For this reason, the only finding of anemia is not indicative of toxicity. No others adverse effects were observed.Conclusion Therapeutic standards for treatment of breast CIP seem to be safe: our experience shows a similar trend in the two groups of patients, not causing myelosuppression as the number of cycles increases.
- Impact of risk factors on oncologic outcomes in intermediate-risk non-muscle-invasive bladder cancer (S03) - Jan 15, 2024 - Abstract #EAU2024EAU_2705;
- Guiding adjuvant instillation in intermediate risk non-muscle invasive bladder cancer by drug screens in patient derived organoids (W06) - Jan 15, 2024 - Abstract #EAU2024EAU_2362;
- | epirubicin / Generic mfg.
Journal: BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer. (Pubmed Central) - Jan 12, 2024
No others adverse effects were observed.Conclusion Therapeutic standards for treatment of breast CIP seem to be safe: our experience shows a similar trend in the two groups of patients, not causing myelosuppression as the number of cycles increases. After surgery or reresection, chemotherapy drugs (epirubicin) or medications such as Bacillus Calmette-Gu
- | Biomarker, Journal, Tumor microenvironment, IO biomarker: Development of a TLR-Based Model That Can Predict Prognosis, Tumor Microenvironment, and Drug Response for Esophageal Squamous Cell Carcinoma. (Pubmed Central) - Jan 11, 2024
High-RS group had a worse survival (p?<?0.01), lower immune checkpoint expression (p?<?0.05), immune cell abundance (p?<?0.05) and decreased sensitivity to Epirubicin (p?<?0.001), 5-fluorouracil (p?<?0.0001), Sorafenib (p?<?0.01) and Oxaliplatin (p?<?0.05). We constructed a TLR-based model, which could be used to assess the prognosis of patients with ESCC, provide new insights into drug treatment for ESCC patients and investigate the TME and drug response.
- || Trial completion date, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P2, N=1460, Active, not recruiting, Sponsor: UNICANCER
We constructed a TLR-based model, which could be used to assess the prognosis of patients with ESCC, provide new insights into drug treatment for ESCC patients and investigate the TME and drug response. Trial completion date: Dec 2023 --> Dec 2024
- | Tyvyt (sintilimab) / Innovent Biologics, Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New trial, Real-world evidence, Real-world: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 11, 2024
P=N/A, N=188, Completed, Sponsor: Sun Yat-sen University
- || Tecentriq (atezolizumab) / Roche
Trial completion date: neoMono: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (clinicaltrials.gov) - Jan 9, 2024
P2, N=416, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2026 --> Aug 2024
- | epirubicin / Generic mfg.
Preclinical, Journal: 3-Indolepropionic acid mitigates sub-acute toxicity in the cardiomyocytes of epirubicin-treated female rats. (Pubmed Central) - Jan 8, 2024
Our findings demonstrate that supplementing endogenously derived 3-IPA can enhance antioxidant protection in the cardiac tissue susceptible to EPI toxicity in female rats. These findings may benefit breast cancer patients undergoing chemotherapy by further validating these experimental data.
- | epirubicin / Generic mfg.
Preclinical, Journal: In vitro characteristics of Epirubicin-loaded thermosensitive liquid embolic agent. (Pubmed Central) - Jan 6, 2024
Epirubicin can be successfully loaded into the thermosensitive liquid embolic agents with good stability and sustained release. After adding iopromide, the drug loading capacity of thermosensitive liquid embolic agents decreased or disappeared.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, P2 data, Journal: The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. (Pubmed Central) - Jan 4, 2024
P2/3
sTK1 activity increased following neoadjuvant therapy for HER2-positive BC but was not associated with patient outcomes or treatment benefit. However, the post-surgery prognostic value in patients that have not attained pCR warrants further investigation.
- ||| epirubicin / Generic mfg., dexrazoxane / Generic mfg.
Retrospective data, Journal, Adverse events, Real-world evidence, Real-world: Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience. (Pubmed Central) - Jan 2, 2024
Among patients receiving anthracycline-containing therapy, patients with BSTSs were more likely to develop cardiac disorders than other tumors. In addition, patients with BSTSs receiving ADM chemotherapy had a higher likelihood of cardiotoxic events than those receiving EPI or L-ADM.
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date: Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (clinicaltrials.gov) - Dec 31, 2023
P3, N=808, Recruiting, Sponsor: Fudan University
- Keytruda (pembrolizumab) / Merck (MSD)
Phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2? breast cancer: KEYNOTE-756 () - Dec 29, 2023 - Abstract #SSO2024SSO_377;
P3
Learning Objectives: Understand the study design of the placebo-controlled phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab + chemotherapy, followed by adjuvant pembrolizumab plus endocrine therapy for early-stage high-risk ER+/HER2? breast cancer Understand pathologic complete response outcomes in the KEYNOTE-756 study Understand residual cancer burden outcomes in the KEYNOTE-756 study
- | chlorogenic acid / Jiuzhang Biotech
Journal: In silico design of novel bioactive molecules to treat breast cancer with chlorogenic acid derivatives: a computational and SAR approach. (Pubmed Central) - Dec 28, 2023
The docking scores of 5-fluorouracil were found to be -5.25 kcal/mol, -3.43 kcal/mol, -3.73 kcal/mol, and -5.29 kcal/mol against PDB IDs 7KCD, 3ERT, 6CHZ, and 3HB5, which indicates the designed compounds have a better docking score than some standard drugs. Taking into account the results of molecular docking, drug likeness analysis, absorption, distribution, metabolism, excretion, and toxicity (ADMET) evaluation, and PASS, it can be concluded that chlorogenic acid derivatives hold promise as potent inhibitors for the treatment of breast cancer.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study. (Pubmed Central) - Dec 24, 2023
The efficacy and safety of the P?+?EC-TH regimen were verified by this study. The HER2-positive breast cancer patients treated with the EC-TH neoadjuvant regimen were more likely to achieve tpCR or bpCR if pyrotinib was administered simultaneously.
- | epirubicin / Generic mfg.
Biomarker, Journal: Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization. (Pubmed Central) - Dec 18, 2023
All patients underwent TACE by DEB loaded with epirubicin and imaging scans after 2 months to evaluate the curative effect according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) standard to determine treatment...However, hypovascular tumor blood supply may result in poor postoperative efficacy and hematuria recurrence. Additionally, multiple bladder tumors may be a risk factor for hematuria recurrence.
- Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids. (Level 1, West Hall; Poster Bd # M11) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_666;
P2
When the primary endpoint is met, a modification of the trial with larger sample size, novel compounds and a focus oncological outcomes is foreseen. Clinical trial information: NCT05024734.
- Tevimbra (tislelizumab) / BeiGene
Punch: Preliminary results from a phase II study of intra?arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC). (Level 1, West Hall; Poster Bd # H3) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_575;
Clinical trial information: NCT05024734. Secondly, angiographic catheter was placed into the internal iliac arteries with Seldinger
- | Journal: Molecular assessment of drug-phospholipid interactions consequent to cancer treatment: a study of anthracycline-induced cardiotoxicity. (Pubmed Central) - Dec 13, 2023
Meanwhile, an ideal membrane consisting of a single type of phospholipids is not capable of capturing the specific interactions of each drug form. These findings confirm that cardiotoxic mechanisms are membrane-layer and drug-form dependent.
- |||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open: TROPION-Breast04: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (clinicaltrials.gov) - Dec 12, 2023
P3, N=1728, Recruiting, Sponsor: AstraZeneca
These findings confirm that cardiotoxic mechanisms are membrane-layer and drug-form dependent. Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. (Pubmed Central) - Dec 11, 2023
The most common grade ?3 adverse events were diarrhea (54.3%), followed by white blood cell count decreased (5.1%), and neutrophil count decreased (4.6%). In conclusion, the neoadjuvant regimen with ECPy-THPy showed promising pathological response and clinical benefits with an acceptable safety profile in patients with stage II-III HER2-positive breast cancer.
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Journal: Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer. (Pubmed Central) - Dec 11, 2023
In conclusion, the neoadjuvant regimen with ECPy-THPy showed promising pathological response and clinical benefits with an acceptable safety profile in patients with stage II-III HER2-positive breast cancer. Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: NeoTOP: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (clinicaltrials.gov) - Dec 7, 2023
P2, N=86, Active, not recruiting, Sponsor: UNICANCER
Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support. Trial completion date: Jun 2023 --> Jun 2024
- 5-fluorouracil / Generic mfg.
Unveiling proteomic diversity: A quantitative study of antibody drug conjugate and chemotherapy targets in gastroesophageal cancer. (Poster Bd # B19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_146;
Topoisomerase 1 (Topo1) is the target for irinotecan or topotecan, and is also the target for some ADCs (e.g. trastuzumab deruxtecan, sacituzumab govitecan etc.)...Another topoisomerase, Topo2A, targetable by etoposide, epirubicin, and doxorubicin, was expressed in 59% of GEC with 19x range (402-7804 amol/?g)... Every cancer is different, and the ability to quantitate simultaneously 72 protein biomarkers from 2-3 FFPE sections provides a wealth of actionable information that, when combined with other multi-omics biomarker data, will help guide clinical treatment or patient stratification for clinical trials.
- | 5-fluorouracil / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study. (Pubmed Central) - Dec 6, 2023
This study suggests an unlikely add-on effect of an anthracycline-based regimen for NAC in HER2-positive breast cancer. Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer.
- | azacitidine / Generic mfg.
New P2 trial, Combination therapy: AZA Combined With RCHOP in P53-mutated DLBCL. (clinicaltrials.gov) - Dec 6, 2023
P2, N=52, Recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Perianal rhabdomyosarcoma in an adult: A case report and review of the literature. (Pubmed Central) - Dec 5, 2023
After 3 cycles of nivolumab, dacarbazine, cisplatin, and vinblastine therapy, a partial response was identified in the patient...The patient received neoadjuvant chemotherapy before surgery and was weak after surgery, so he did not receive chemoradiotherapy. The patient succumbed after 11 months postoperatively due to widespread intraabdominal metastasis.
- | Rituxan (rituximab) / Roche
Enrollment closed: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Dec 5, 2023
P2, N=60, Active, not recruiting, Sponsor: Henan Cancer Hospital
The patient succumbed after 11 months postoperatively due to widespread intraabdominal metastasis. Recruiting --> Active, not recruiting
- | cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy. (Pubmed Central) - Dec 4, 2023
Finally, the inhibition of pyruvate entry into mitochondria with UK-5099 reduced OXPHOS and re-sensitized persistent cells to therapeutic agents. Together, these findings suggest that targeting mitochondrial pyruvate metabolism may help to overcome mitochondrial adaptation of chemo-persistent TNBC.
- ||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
P3 data, Journal, HEOR: Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. (Pubmed Central) - Dec 4, 2023
P3
CMF had worse QOL effects than did capecitabine, which were persistent for 24 months. The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
P1/2 data, Journal: Phase 1/2 Study of the Timing and Efficacy of 3?mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols. (Pubmed Central) - Dec 4, 2023
Post chemotherapy 24-hour timing of peg-GCSF administration remains as the standard. A phase 3 trial of 6?mg versus 3?mg is warranted.
- | epirubicin / Generic mfg.
Journal: New thiophene-1,3,4-oxadiazole-thiazolidine-2,4-dione hybrids: Synthesis, MCF-7 inhibition and binding studies. (Pubmed Central) - Nov 30, 2023
The docking score of TOT derivativeswas substantially identical to the docking score of epirubicin hydrochloride. The designed molecules complied with the requirements for drug-likeness and ADME.
- | Cosela (trilaciclib) / G1 Therap
Enrollment open: SMA-BC-002: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (clinicaltrials.gov) - Nov 30, 2023
P2, N=116, Recruiting, Sponsor: wang shusen
The designed molecules complied with the requirements for drug-likeness and ADME. Not yet recruiting --> Recruiting
- | Journal: Sphingolipid-Based Synergistic Interactions to Enhance Chemosensitivity in Lung Cancer Cells. (Pubmed Central) - Nov 28, 2023
Loaded cells with fluorescent sphingomyelin analog (BODIPY) and mCherry-EGFP-LC3B were used to track autophagic flux and assess cytotoxicity when cells are exposed to chemotherapy (epirubicin, cisplatin, and paclitaxel) together with sphingolipid pathway inhibitors and autophagy modulators...Results showed significant synergy, especially when combining epirubicin with autophagy inducers (rapamycin and Torin), reducing cell viability...Further research is needed to identify specific sphingolipids accumulating in autophagosomes. These findings offer insights into potential strategies for overcoming chemotherapy resistance by targeting the sphingolipid pathway.
- | Trial completion: MEMORI: Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (clinicaltrials.gov) - Nov 28, 2023
P2, N=75, Completed, Sponsor: Technical University of Munich
These findings offer insights into potential strategies for overcoming chemotherapy resistance by targeting the sphingolipid pathway. Unknown status --> Completed
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: Modulation of SLFN11 induces changes in DNA Damage response in breast cancer. (Pubmed Central) - Nov 25, 2023
Our results show that induction of SLFN11 expression can enhance DDA and DDR sensitivity in breast cancer cells and dCas9 systems may represent a novel approach to increase SLFN11 and achieve higher sensitivity to chemotherapeutic agents, improving outcome or decreasing required drug concentrations. SLFN11-targeting therapies might be explored pre-clinically to develop personalized approaches.
- | Biomarker, Journal, Tumor microenvironment, PARP Biomarker, IO biomarker: Oxidative stress and autophagy-mediated immune patterns and tumor microenvironment infiltration characterization in gastric cancer. (Pubmed Central) - Nov 22, 2023
The low-OARGscore group was predicted to benefit more from Ribociclib, Alisertib, Niraparib, Epirubicin, Olaparib, and Axitinib, while patients in the high-OARGscore group were predicted to benefit more from Afatinib, Oxaliplatin, Paclitaxel, 5-Fluorouracil, Dabrafenib and Lapatinib. Our findings offer a specific method for predicting a patient's prognosis and susceptibility to immunotherapy, as well as a promising insight of oxidative stress and autophagy in GC.
- |||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer (clinicaltrials.gov) - Nov 22, 2023
P3, N=160, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Darzalex (daratumumab) / J&J
New P2 trial: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2023
P2, N=54, Recruiting, Sponsor: Wuhan Union Hospital, China
- | Journal: Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an alternative platinum-containing regimen in 116 patients with early triple negative breast cancer. (Pubmed Central) - Nov 20, 2023
ddDCEP was more cost-effective than contemporary carboplatin-based regimens. This novel approach offers an economically viable and effective alternative to current chemoimmunotherapy regimens, and merits further investigation.
- | epirubicin / Generic mfg.
Journal: Predictive Potential of RNA Polymerase B (II) Subunit 1 (RPB1) Cytoplasmic Aggregation for Neoadjuvant Chemotherapy Failure. (Pubmed Central) - Nov 18, 2023
We found that cytoplasmic foci of RPB1 occur in larger sizes in tumors that showed no regression after therapy. Based on these results, we propose that monitoring the cytoplasmic aggregation of RPB1 may be suitable for determining-from biopsy samples taken before treatment-the effectiveness of neoadjuvant chemotherapy.
- || cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, Immunomodulating: Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients. (Pubmed Central) - Nov 18, 2023
Underlying differences in the induced cell death might be causal. These divergent immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel should be considered when planning future combinations with immunotherapies in breast cancer.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal: Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - Nov 15, 2023
P3
These findings support the use of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab as a standard-of-care therapy for patients in Asian countries with early triple-negative breast cancer. ClinicalTrials.gov Identifier: NCT03036488.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date, Metastases: PILHLE-001: Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial (clinicaltrials.gov) - Nov 14, 2023
P2, N=48, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT03036488. Trial primary completion date: May 2023 --> Sep 2023
- || 5-fluorouracil / Generic mfg.
Review, Journal: Updated Adjuvant Chemotherapy for Gastric Cancer. (Pubmed Central) - Nov 14, 2023
In recent years, perioperative therapy using novel agents, such as molecular-targeted drugs and immune checkpoint inhibitors (ICIs), has also been tested and evaluated in the three major regions (East Asia, Europe, and North America) with promising results. Perioperative chemotherapy has become an integral part of many treatment strategies and requires continued research and evaluation.